Cabaletta Bio

CABA Rare disease Lead: Phase 2 ★ Read the deep dive → 10 Biotech Distilled articles ↓

Most recent annual filing: 2026-01-15

Catalyst timeline

Rese-cel (CABA-201) - RESET-SLE and2H 2026Rese-cel (CABA-201) - RESET-SLE and, 2H 2026, notable
PV / SLE Cellares manufacturing2H 2026PV / SLE Cellares manufacturing, 2H 2026, routine
SSc-ILD registrational study pivotal start4Q 2026SSc-ILD registrational study pivotal start, 4Q 2026, notable
Rese-cel (CABA-201) - Myositis BLA2027Rese-cel (CABA-201) - Myositis BLA, 2027, material
RESET-Myositis pivotal toplineMid-2027RESET-Myositis pivotal topline, Mid-2027, major
Myositis BLA filing2H 2027Myositis BLA filing, 2H 2027, notable
Myositis BLA JDM filing2H 2027Myositis BLA JDM filing, 2H 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

resecabtagene autoleucel

rese-cel · CABA-201

Cell Target: CD19

Systemic Lupus Erythematosus Phase 1 Phase 1/2 trial intravenous NCT06121297
Lupus Nephritis Phase 1 Phase 1/2 trial intravenous NCT06121297
Dermatomyositis Phase 1 Phase 1/2 trial intravenous NCT06154252
Immune-Mediated Necrotizing Myopathy Phase 1 Phase 1/2 trial intravenous NCT06154252
Systemic Sclerosis Phase 1 Phase 1/2 trial intravenous
Generalized Myasthenia Gravis Phase 1 Phase 1/2 trial intravenous NCT06359041
Pemphigus Vulgaris Phase 1 intravenous NCT04422912
SSc-Associated Interstitial Lung Disease intravenous

Technology platforms

CABA

Cabaletta Approach to B cell Ablation (CABA) platform using the CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) approach, designed to reset the immune system via deep B cell depletion. Focus area: broad range of autoimmune diseases with B cell involvement.

Targets: CD19

Cell Shuttle · Cellares

Cellares Cell Shuttle — automated, closed, end-to-end CAR T cell manufacturing platform designed to improve reproducibility, scalability, and process control for autologous cell therapy production; applied to rese-cel manufacturing in the RESET clinical program

Biotech Distilled coverage (10)

2026-09-15 UPDATE: Cabaletta Bio (CABA) - The Warrant Wall Came Down, and It Paid 🔒 Paid
2026-08-14 UPDATE: Cabaletta Bio (CABA) - Down 24% on No Bad News 🔒 Paid
2026-06-03 UPDATE: Cabaletta Bio (CABA) - The Third Gate Just Cracked Open
2026-05-15 UPDATE: Cabaletta Bio (CABA) - The No-Chemo Gambit Actually Worked at the Lowest Dose 🔒 Paid
2026-05-04 UPDATE: Cabaletta Bio (CABA) - The Dilution Gap Just Closed. And Eli Lilly Brought a Chair.
2026-04-29 UPDATE: Cabaletta Bio (CABA) - The Factory Just Got Locked In for a Decade 🔒 Paid
2026-03-29 UPDATE: Cabaletta Bio (CABA) - The FDA Hits the Brakes on the Fast Track 🔒 Paid
2026-02-21 UPDATE: Cabaletta (CABA) - The Smart Money is Anchoring 🔒 Paid
2026-01-13 Update: Cabaletta Bio (CABA) – The 2026 Strategy Reset 🔒 Paid
2026-01-08 Cabaletta Bio (CABA): Scientific Due Diligence for Rese-Cel and Pipeline Products

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.